Have you ever taken your old compact discs and converted them to MP3 files so you could listen to your favorite music on your laptop, or through a portable MP3 device that’s much smaller than an unwieldy portable CD player? Now, researchers from the University of Glasgow are working on a very similar process, but instead of music files, they are using a chemical-to-digital converter to digitize the process of drug manufacturing; a chemical MP3 player, if you will, that can 3D print pharmaceuticals on demand.
3D printing in the pharmaceutical field is a fascinating concept, though not a new one. But this ‘Spotify for chemistry’ concept is new: it’s the first time we’ve seen an approach to manufacturing pharmaceuticals using digital code. According to Science, the University of Glasgow team “tailored a 3D printer to synthesize pharmaceuticals and other chemicals from simple, widely available starting compounds fed into a series of water bottle–size reactors.”The digital code is used by the 3D printer to make a portable factory, which can make the drug by adding chemicals in a pre-defined, fail-safe sequence, making it possible for users to synthesize nearly any compound. This new method could change the world of pharmaceuticals as we know it, as it could be used to significantly increase how many useful drugs are readily available, regardless of their patent-life, because they won’t need to be made in dedicated manufacturing facilities.
Professor Leroy (Lee) Cronin, the University of Glasgow’s Regius Chair of Chemistry; he designed and developed the new approach. “We will also use this approach to make a ‘Spotify for chemistry’, allowing scientists to develop better code to make important chemicals.”“This approach is a key step in the digitization of chemistry, and will allow the on demand production of chemicals and drugs that are in short supply, hard to make at big facilities, and allow customisation to tailor them to the application,” said
Cronin and his team, with funding from the university’s complex chemistry initiative, the European Research Council, and the Engineering and Physical Sciences Research Council, described their method in a paper, titled “Digitization of multistep organic synthesis in reactionware for on-demand pharmaceuticals,” and demonstrated the system’s potential by using it to produce muscle relaxer Baclofen, which can treat muscle symptoms like stiffness, spasm, and pain, caused by multiple sclerosis.
Cronin’s first attempt to democratize chemistry was back in 2012, when he and his colleagues published a paper about what he referred to as reactionware – 3D printed chemical reaction vessels that contained catalysts and other components for carrying out specific reactions. His team could synthesize several simple compounds just by adding the starting components, but many thought that the method could never be used to make complex compounds like pharmaceuticals.
The abstract reads, “Chemical manufacturing is often done at large facilities that require a sizable capital investment and then produce key compounds for a finite period. We present an approach to the manufacturing of fine chemicals and pharmaceuticals in a self-contained plastic reactionware device. The device was designed and constructed by using a chemical to computer-automated design (ChemCAD) approach that enables the translation of traditional bench-scale synthesis into a platform-independent digital code. This in turn guides production of a three-dimensional printed device that encloses the entire synthetic route internally via simple operations. We demonstrate the approach for the γ-aminobutyric acid receptor agonist, (±)-baclofen, establishing a concept that paves the way for the local manufacture of drugs outside of specialist facilities.”
But he continued his work, and this paper explains how his team was able to 3D print several interconnected reaction vessels, or modules, on an Ultimaker 3D printer. The reaction vessels can complete four different chemical reactions when the proper solvents and reagents are added at the right time and in the right order – all you need is a simple instruction manual.
According to the researchers, this new ability to 3D print drug factories on demand could help personalize drug delivery to individual patients’ needs, not to mention lower costs, increase what choices are available to doctors, and reduce the counterfeiting risk – each reactionware setup, in theory, would only be able to produce one type of medicine.
Cronin told Chemistry World, “The chemist now becomes a digital designer.”
“Lots of compounds that are extremely important for chemistry, biology and medical science cost more than $1 million (£720,000) per mole. We’ve been starting to make kits for these and it cuts the cost dramatically,” Cronin explained.
However, regulation will be incredibly important if the process is commercialized, so people aren’t making dangerous narcotics in their kitchens.
Agencies like the FDA would need to overhaul their rules for validating how safe medications are, and make sure that the reactionware is making the desired medication, instead of just validating manufactured drug samples and the production facilities. But Cronin believes it’s important to continue the work, as the potential benefits of 3D printing drug factories far outweigh the negatives. One idea he has is to include a final module with future printed reactors, which have standard validation tests that produce a visual readout at the end of the process, similar to pregnancy tests.
“I think it’s manageable,” Cronin said.
Discuss this and other 3D printing topics at 3DPrintBoard.com or share your thoughts in the Facebook comments below.[Source: University of Glasgow]
You May Also Like
3D Systems Fills in Metal 3D Printing with Processing Partnership via GF Machining Solutions
Now that additive manufacturing (AM) is being increasingly integrated into end production, OEMs are recognizing that their equipment needs to more adequately fit into typical manufacturing workflows. They also realize...
3D Printing Webinar and Virtual Event Roundup, July 19, 2020
A variety of topics will be covered in this week’s webinar and virtual event roundup, including additive manufacturing in aerospace, CAMWorks, product management, post-processing, and more. Read on to learn...
DyeMansion Launches Global Post-Processing Partner Network for 3D Printing
German post-processing equipment manufacturer DyeMansion has announced the creation of a global partner network. The group is made up of 46 of DyeMasion’s sales and service partners across 19 different...
Velo3D Lands Largest Metal 3D Printer Order to Date, from Aerospace Customer
Recently, Velo3D received its largest order in company history since its launch commercially in 2018. An existing aerospace customer placed an order worth $20 million for Velo3D’s innovative, industrial metal...
View our broad assortment of in house and third party products.